28,748 Shares in Kura Oncology, Inc. (NASDAQ:KURA) Purchased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 28,748 shares of the company’s stock, valued at approximately $250,000.

Several other large investors have also recently bought and sold shares of KURA. Point72 Asset Management L.P. bought a new position in shares of Kura Oncology during the third quarter worth approximately $3,695,000. Wealthfront Advisers LLC bought a new position in Kura Oncology during the 4th quarter worth $1,289,000. Barclays PLC lifted its holdings in shares of Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after buying an additional 84,563 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at about $623,000. Finally, SG Americas Securities LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at about $436,000.

Analyst Ratings Changes

Several analysts have weighed in on the stock. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. JMP Securities reiterated a “market outperform” rating and issued a $28.00 price target on shares of Kura Oncology in a research note on Thursday, February 6th. Scotiabank lowered their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. StockNews.com upgraded Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last quarter. 5.50% of the stock is owned by company insiders.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $5.89 on Friday. The company’s 50 day moving average price is $7.68 and its two-hundred day moving average price is $11.57. The firm has a market capitalization of $475.65 million, a P/E ratio of -2.50 and a beta of 0.83. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology, Inc. has a fifty-two week low of $5.82 and a fifty-two week high of $23.48.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. On average, equities analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.